IN BRIEF : Zantac wins over-the-counter clearance
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Glaxo Wellcome, the pharmaceuticals group, has won regulatory approval for its non-prescription version of Zantac, its anti-heartburn treatment. The clearance opens up a new market for Zantac, competing with rival treatments such as Pepcid, produced by Merck, and Tagamet, from SmithKline Beecham.
Glaxo will market the drug in its lower-dosage Zantac 75 form. Zantac, which is the world's biggest-selling prescription medicine and is used in the treatment of ulcers, should be available in the US early next year. It will be sold through Warner Lambert, Glaxo Wellcome's US joint venture. The announcement comes a day after Glaxo announced it was selling its half-share in Warner Wellcome, the group that markets cough and cold cures such as Actifed. Warner Lambert is paying pounds 682m for the share.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments